Ipamorelin Dosing in Research: Doses, Routes, and Half-Life Context
Read this first
This page describes Ipamorelin doses only as they appear in published research — what was given to which species, by which route, for how long. It is not a protocol and not a recommendation. There is no approved human dose of ipamorelin, because the compound is not approved [3]. The community combination protocols you may have seen (paired with CJC-1295, given under the skin) have no peer-reviewed human dosing basis and are described here as anecdotal, not recommended. Where a number appears below, it is attached to its study. Nothing on this page tells anyone to take anything.
Doses used in human studies
Two human datasets define the studied range. In the PK/PD study, healthy male volunteers received single 15-minute IV infusions at 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg, producing dose-proportional kinetics [2]. In the only efficacy trial, bowel-resection patients received 0.03 mg/kg IV twice daily for up to 7 days — a regimen that missed its primary endpoint [3]. Both were intravenous and clinic-administered. Neither establishes a self-administration dose, and the dominant real-world route (subcutaneous) has no published human PK characterization at all [3].
Doses used in animal studies
Rodent work spans a range. Subcutaneous ipamorelin at 18, 90, and 450 µg/day (divided three times daily, 15 days) dose-dependently increased rat longitudinal bone growth [4]. A continuous-infusion bone-mineral study used 0.5 mg/kg/day via osmotic minipump over 12 weeks. Rat postoperative-ileus work used 0.1–1 mg/kg IV repeated four times daily. The 2024 ferret cachexia study used 1–3 mg/kg intraperitoneal [5]. These are species- and model-specific research doses; none translates to a human regimen.
Routes studied
Ipamorelin has been administered intravenously (human PK and clinical trials; rodent efficacy) [2][3], subcutaneously (rodent bone and body-composition studies, and the dominant route in community use) [4], intranasally (rodent PK, ~20% bioavailability), and intraperitoneally (rodent/ferret efficacy) [5]. Oral dosing applies only to engineered ipamorelin-derived analogs such as NN703 (~30% oral bioavailability in dogs) [7] — ipamorelin itself is not orally bioavailable. The route matters for kinetics and for any safety interpretation: the human half-life figures come specifically from IV dosing [2].
Half-life and timing
In healthy human volunteers the terminal half-life is approximately 2 hours (IV), with clearance 0.078 L/h/kg and steady-state volume of distribution 0.22 L/kg; the GH response is a single discrete pulse peaking about 40 minutes (0.67 h) after dosing [2]. In rats, plasma clearance is roughly 5-fold lower than GHRP-6 [1]. The full time-in-system breakdown — and why "2-hour half-life" does not mean "out of your system in 2 hours" — is on the dedicated half-life page.
How much cjc-1295 ipamorelin should i take
There is no answer to this that any published human trial supports — and this page does not provide a dose. The CJC-1295 + ipamorelin combination has never been tested for dosing in a controlled human study; its support is single-agent pharmacology plus animal work, and a 2026 review that found a muscle effect in mice explicitly noted evidence is limited to animal studies [18]. Community subcutaneous "stack" regimens exist but have no peer-reviewed human dosing basis and are anecdotal, not recommended [3]. Anyone weighing this should understand that no validated dose, schedule, or safety-monitoring framework exists for the combination in humans [17].
How to reconstitute cjc-1295 ipamorelin 5mg
This is the most-searched handling question, and the honest answer is a research-handling description, not a preparation instruction for use. Ipamorelin is supplied as a lyophilized (freeze-dried) powder — free base or acetate salt — and in the research-supply literature is reconstituted with bacteriostatic water for handling. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. These are general peptide-handling observations from the research-supply literature, not a clinical preparation instruction, and the "5mg" figure is a vial-labeling convention from suppliers, not a validated dose. No human dosing is implied or provided.